Formed in 2020 through the combination of Mylan and Upjohn, Viatris develops and manufactures medicines spanning generics, established brands and innovative therapies. Its global manufacturing and scientific network supports access to treatments across more than 165 countries and territories, with about one billion patients receiving its medicines annually. In Austria, the group includes Viatris Austria GmbH and Arcana Arzneimittel GmbH, with 72 employees and nine European production sites.
National Association of Boards of Pharmacy Accreditation
Registration
NABPACCREDITATION
Quality certification